

## Using optogenetics to translate the “inflammatory dialogue” between heart and brain in the context of stress

Jinbo Cheng<sup>1,2</sup>, Jie Zhang<sup>2</sup>, Caiyi Lu<sup>1</sup>, Liping Wang<sup>2</sup>

<sup>1</sup>*Institute of Geriatric Cardiology, PLA General Hospital, Beijing 100853, China*

<sup>2</sup>*Shenzhen Key Laboratory of Neuropsychiatric Modulation, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China*

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2012

**Abstract:** Inflammatory processes are an integral part of the stress response and are likely to result from a programmed adaptation that is vital to the organism’s survival and well-being. The whole inflammatory response is mediated by largely overlapping circuits in the limbic forebrain, hypothalamus and brainstem, but is also under the control of the neuroendocrine and autonomic nervous systems. Genetically predisposed individuals who fail to tune the respective contributions of the two systems in accordance with stressor modality and intensity after adverse experiences can be at risk for stress-related psychiatric disorders and cardiovascular diseases. Altered glucocorticoid (GC) homeostasis due to GC resistance leads to the failure of neural and negative feedback regulation of the hypothalamic–pituitary–adrenal axis during chronic inflammation, and this might be the mechanism underlying the ensuing brain and heart diseases and the high prevalence of co-morbidity between the two systems. By the combined use of light and genetically-encoded light-sensitive proteins, optogenetics allows cell-type-specific, fast (millisecond-scale) control of precisely defined events in biological systems. This method is an important breakthrough to explore the causality between neural activity patterns and behavioral profiles relevant to anxiety, depression, autism and schizophrenia. Optogenetics also helps to understand the “inflammatory dialogue”, the inflammatory processes in psychiatric disorders and cardiovascular diseases, shared by heart and brain in the context of stress.

**Keywords:** stress; inflammatory processes; glucocorticoid resistance; psychoneuroimmunology; psychiatric disorders; cardiovascular disease; neuronal circuits; optogenetics

### 1 Introduction

Events that disturb or potentially disturb a complex organism’s homeostasis or well-being (known as stressors) recruit stress-response systems involving behavioral, cardiovascular, metabolic, and immunological changes that

are not mutually exclusive but may act together as one integral event<sup>[1]</sup>. The interaction between the autonomic nervous system (ANS) and the hypothalamic–pituitary–adrenocortical (HPA) axis is essential for adaptation to stress<sup>[2]</sup>. The pattern and magnitude of a stress response vary with different stressors, and result in different coping strategies. Factors that affect the activation and control of the ANS and the HPA axis include duration of stress exposure (acute *versus* chronic), type of stress (physical *versus* psychological), developmental stage at exposure (early life

Corresponding authors: Liping Wang, Caiyi Lu  
Tel: +86-755-86392218; Fax: +86-755-86392299  
E-mail: lp.wang@siat.ac.cn; cylvu2000@sina.com  
Article ID: 1673-7067(2012)04-0435-14  
Received date: 2012-03-22; Accepted date: 2012-05-07

versus adulthood), and the genetic background of the organism<sup>[3]</sup>.

One breakthrough in psychoneuroimmunology in the past two decades was the realization that psychological stress responses are themselves examples of inflammatory responses<sup>[1,4]</sup>. The central nervous system (CNS) determines the primary profile of an inflammatory response to a stressor through “hardwiring” of sympathetic and parasympathetic innervation of mainly the lymphoid organs<sup>[5]</sup>. The mechanism of these inflammatory responses lies in the integration of multiple chemical inflammatory messengers and their receptors<sup>[3,6]</sup>. These inflammatory mediators include small molecules [e.g. free radicals and prostanoids such as prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)], neurotransmitters (e.g. noradrenalin, acetylcholine, and serotonin), neuroendocrine peptides (e.g. corticotropin-releasing factor), steroid hormones (e.g. cortisol in humans and corticosterone in rodents), transcription factors [e.g. nuclear factor kappa B (NF- $\kappa$ B)], pro-inflammatory cytokines [e.g. interleukins IL-1 $\beta$  and IL-6 and tumor necrosis factor alpha (TNF- $\alpha$ )], and the anti-inflammatory cytokine IL-10. These inflammatory responses occur both peripherally and within the brain, secondary to or simultaneously with the onset of peripheral inflammatory responses<sup>[7-9]</sup>. In the context of stress, dysfunction of the neuronal and negative feedback regulation of the HPA axis accounts for prolonged inflammatory responses to stress, under which glucocorticoid (GC) resistance may be a general mechanism<sup>[10,11]</sup>. Coupled with factors that affect GC availability, these pro-inflammatory cytokines *de novo* would worsen this abnormal modulation and therefore initiate a self-amplifying vicious cycle of inflammatory responses<sup>[10]</sup>. Moreover, accumulating evidence shows that stress-induced inflammatory responses in early life program vulnerability to later-life stress responses<sup>[12,13]</sup>, ultimately leading to inflammation-related diseases such as major depression, type 2 diabetes mellitus, and cardiovascular disease (CVD)<sup>[14-16]</sup>. This review focuses on stress-induced chronic inflammatory processes characterized by hyperactivity of the HPA axis and increased production of pro-inflammatory cytokines dominated by GC resistance<sup>[17-19]</sup>. Moreover, these inflammatory processes

may induce an “inflammatory dialogue” between heart and brain in the context of stress, accounting for the pathogenesis of major depression, CVD, and their co-morbidities. Optogenetics, a new method that combines optical and genetic manipulations, can help to translate this elusive “dialogue”. Optogenetics enables the identification of novel therapeutic targets based on neuronal circuit mechanisms in the limbic regions in a top-down manner due to its advantages (cell-type specificity, and high spatial and temporal resolution), and is becoming essential for both basic and clinical research on the common mechanisms in stress-related diseases.

## 2 Mechanisms underlying inflammatory responses under stress

Psychological stress occurs when environmental demands exceed adaptive capacity<sup>[14,20]</sup>. Psychological stressors are processed in the limbic forebrain, including the amygdala, hippocampus and prefrontal cortex (PFC). The responses processed by these circuits occur in anticipation of or in reaction to stressful events, on the basis of prior experiences or innate programs<sup>[20]</sup>. All these parts of the limbic region work in parallel to integrate the activation of the HPA axis and the ANS<sup>[2]</sup>.

Both acute and chronic psychological stress induce a series of inflammatory responses to help an individual survive<sup>[1]</sup>. In healthy humans, exposure to acute laboratory stressors induces the elevation of markers of innate immunity and a general suppression of adaptive immunity<sup>[21]</sup>. However, exposure to real-life chronic stressors is associated with a biphasic immune response, partial suppression of cellular and humoral functions accompanied by low-grade, nonspecific inflammation<sup>[21]</sup>. Psychological stress induces pronounced changes in the innate and adaptive immune responses, which are predominantly controlled by neuroendocrine mediators from the HPA axis and the sympathetic adrenal axis<sup>[14]</sup>. Psychological stress has also been found to impair vagal tone, resulting from the withdrawal of inhibitory motor vagal input that inhibits pro-inflammatory cytokine release through interaction with the acetylcholine receptor  $\alpha 7$  subunit of the nicotinic acetylcholine

receptor<sup>[22,23]</sup>. Therefore, vagal withdrawal in response to stress may also intensify inflammatory processes.

Increased sympathetic adrenal activity appears to play a major role in immune changes under acute psychological stress<sup>[1]</sup>. On detection of a homeostatic challenge, the brain activates the sympathetic nervous system (SNS) to release the catecholamines noradrenalin (primarily from the SNS) and adrenalin (primarily from the adrenal medulla). By sympathetic innervation of lymphoid organs and the sympathetic-adrenal axis, through noradrenalin and adrenalin binding with  $\beta$ -adrenoreceptors on the immune cells, and in some subsets through  $\alpha$ -adrenoreceptors, the ANS can alter the circulation of leukocyte subpopulations and enhance the production and release of pro-inflammatory cytokines by influencing the functional capacity of innate immunocompetent cells (monocytes/macrophages)<sup>[24]</sup>. Chronic  $\beta$ -adrenoreceptor stimulation also increases the myocardial gene expression and protein production of pro-inflammatory cytokines, including IL-1 $\beta$ , IL-6, and TNF- $\alpha$ <sup>[25]</sup>. All these peripheral pro-inflammatory cytokines in turn influence the inflammatory processes in the CNS<sup>[11]</sup>. The initial stress-induced increase in inflammatory activity is predominantly mediated by catecholamines; HPA axis activity also participates. GCs exert “permissive” effects on the synthesis of adrenalin and in noradrenalin signaling, as is common in endocrine events<sup>[26]</sup>.

The HPA system is the final common pathway in the mediation of the stress response<sup>[2]</sup>. Following the initial sympathetic adrenal activity, stress also triggers the activation of the medial parvocellular neurons in the paraventricular nucleus (PVN) of the hypothalamus, inducing the release of corticotropin-releasing hormone (CRH) and co-secretagogues such as arginine vasopressin (AVP) into the portal vessels of the median eminence. Secretagogues travel through the portal blood to the anterior pituitary where they induce the secretion of adrenocorticotrophic hormone (ACTH). Subsequently, ACTH, by means of systemic circulation to the adrenal cortex, induces GC synthesis and secretion<sup>[20]</sup>. CRH-expressing neurons in the PVN project not only to the median eminence but also to other areas such as the locus coeruleus, through noradrenergic neu-

rons, resulting in noradrenalin release at nerve terminals distributed widely in the CNS, and thereby regulate adrenal innervation and the sensitivity of the adrenal cortex to ACTH through the ANS<sup>[27-29]</sup>. Yet, activation of the HPA axis resulting in elevation of circulating GCs occurs more slowly than the sympatho-adrenomedullary activation, which ensures an amplified and relatively protracted secretory episode<sup>[2]</sup>. The coupling of HPA axis activity with the sympathetic mechanisms and other signaling pathways of inflammatory mediators are mainly responses to chronic psychological stress, and they show remarkable individual variability in vulnerability to inflammation-related disease<sup>[8,15,30]</sup>.

### 3 Integration of peripheral and central neurogenic inflammation in the context of stress

The brain is central to stress responses and plays a crucial role in initiating, organizing, adapting, and restraining inflammatory responses to stress<sup>[7,9,31,32]</sup>. The CNS hosts processes of inflammatory responses to stress with features similar to those hosted by the peripheral system<sup>[26]</sup>. The link between stress and inflammatory responses within the CNS and the peripheral system is considered to be a well-organized programming process, as almost all levels of such responses become activated; that is, stress operates on the genetic, mediator, and executive levels, with a corresponding increase in the levels of inflammatory markers.

**3.1 Inflammatory signals from periphery to brain** Having no classic lymphatic drainage, the brain was considered an immunologically privileged organ separated from the peripheral immune system by the blood-brain barrier (BBB). However, current evidence suggests that extensive communication exists between the CNS and the immune system, accounting for various essential, coordinated stress responses<sup>[33]</sup>. The brain also houses immune cells, such as macrophages and dendritic cells in the choroid and meninges. When exposed to inflammatory stimuli, parenchymal macrophages (known as microglia) produce pro-inflammatory cytokines and prostaglandins that bind to their receptors on neuronal and non-neuronal brain cells<sup>[34]</sup>.

Generally, exposure to acute or chronic stressors is associated with the immunosuppressive aspect of the adap-

tive immune response, especially the proliferative ability of T and B cells *in vitro*; however, these stressors can also activate the innate immune response<sup>[35]</sup>. The brain monitors peripheral immune responses by several parallel processes: (1) In the neural pathway<sup>[36]</sup>, peripherally produced cytokines from activated monocytes and macrophages stimulate primary afferent nerves, such as the vagus. Vagal afferents project to the nucleus tractus solitarius, from where information is relayed to the ventrolateral medulla, PVN, central amygdala, and bed nucleus of the stria terminalis. (2) In the humoral pathway<sup>[37]</sup>, the macrophage-like cells residing in the circumventricular organs (CVOs) and the choroid plexus generate pro-inflammatory cytokines. As the CVOs lie outside the BBB, these cytokines can enter the brain by volume diffusion through the leaky regions such as the median eminence, organum vasculosum of the lamina terminalis, area postrema, and subfornical organ. (3) The overflowing pro-inflammatory cytokines in the systemic circulation can access the brain through saturable cytokine-specific transport molecules on brain endothelium, and activation of endothelium is responsible for the subsequent release of secondary messengers such as PGE<sub>2</sub> and nitric oxide<sup>[38]</sup>. (4) Special cytokines such as IL-1 can interact with their receptors located on the perivascular macrophages and endothelial cells of brain venules, resulting in the local production of PGE<sub>2</sub><sup>[7]</sup>.

The immune system – brain communication ultimately leads to the production of pro-inflammatory cytokines by microglia, and they, combined with the inflammatory mediators (such as PGE<sub>2</sub>) and reactive nitrogen and oxygen species released from activated microglia, induce mutual activation of astrocytes, thereby amplifying the inflammatory signals within the CNS<sup>[39]</sup>. NF-κB, an inflammatory signaling molecule, is an essential mediator at the blood-brain interface, and communicates peripheral inflammatory signals to the CNS<sup>[33]</sup>. Moreover, the whole process requires the convergent action of two events with different temporal niches: the rapid activation of the afferent neural pathway and the slower propagation of the cytokine message within the brain<sup>[34]</sup>.

### 3.2 GC resistance dominates the profile of the CNS

**cytokine network under stress** Cytokines are soluble bioactive mediators released by various cell types both in the periphery (macrophages and lymphocytes) and in the brain (neurons, astrocytes, and microglia). They are important inflammatory mediators in stress, and function within a complex network either synergistically or antagonistically<sup>[9,40]</sup>. Complex interactions exist between cytokines, inflammation, and the adaptive responses to maintain homeostasis<sup>[41]</sup>. Within the brain, cells that produce cytokines, express cytokine receptors, and amplify inflammatory signals (neurons, astrocytes, and microglia)<sup>[39]</sup>, are the substrate of immune signals. These immune signals, including hyperactivation of the HPA axis and CRH coupled with alteration of the metabolism of key monoamines (e.g., serotonin, dopamine, and noradrenalin), play a role in the potent effects of peripheral pro-inflammatory cytokines on pathways involved in the pathophysiology of neuropsychiatric disorders such as depression<sup>[35]</sup>.

Pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, activate the HPA axis at multiple levels (hypothalamus, anterior pituitary, and adrenal cortex) and by multiple mechanisms<sup>[42]</sup>. This effect is usually attributed to the elevated production of CRH and circulating GCs<sup>[43]</sup>; however, the underlying mechanisms are yet to be investigated. Cytokines can influence HPA axis function via their effects on negative feedback regulation<sup>[17]</sup>, and impaired negative feedback regulation of the HPA axis has been shown to lead to GC resistance manifested by increased cortisol concentrations following dexamethasone (DEX) administration in a DEX suppression test and a DEX-CRH test<sup>[44]</sup>. A non-suppressive effect in the DEX-CRH test is also found in patients with flattening of the diurnal cortisol slope and increased evening cortisol concentrations, resulting in adverse behavioral effects such as depression as well as medical disorders including CVD and cancer, with poor outcomes<sup>[45,46]</sup>. The decreased feedback regulation of the HPA axis by GCs is believed to be partly mediated by alteration of the GC receptor (GR)<sup>[44,45]</sup>.

During chronic inflammatory responses, pro-inflammatory cytokines can incur GC resistance in immunocytes and their cellular targets through a cascade of activation of NF-κB,

p38 mitogen-activated protein kinase, and signal transducer and activator of transcription 5<sup>[47]</sup>, thereby translocating GR from the cytoplasm to the nucleus and inhibiting GR-DNA binding through nuclear protein-protein interaction<sup>[47]</sup>. Cytokines can also influence GR expression by decreasing GR $\alpha$  (the active form of the receptor) and increasing GR $\beta$  (a relatively inert isoform)<sup>[18]</sup>. At the hypothalamic level, this cytokine-dependent GC resistance pathway might be the underlying mechanism for the reduced ability of GCs to downregulate the production of CRH<sup>[34]</sup>. Yet, at the peripheral (monocytes/macrophages) and central innate (monocytes/macrophages and microglia) immune systems, the inhibitory effect of GCs on cytokine production and action decreases and gives way to a feed-forward cascade of increased production of pro-inflammatory cytokines<sup>[34]</sup>. In the brain, these increased inflammatory responses *de novo* result in downregulated inhibitory feedback of GCs on CRH, thereby intensifying the stress-response system<sup>[11]</sup>. Moreover, CRH can directly enhance the production of pro-inflammatory cytokines in macrophages<sup>[48]</sup>. The hypersecretion of CRH through the projection from CRH-expressing neurons in the PVN to noradrenergic neurons in the locus coeruleus results in noradrenalin release, ultimately leading to the elevation of SNS outflow<sup>[27,28]</sup>. Catecholamines released from sympathetic nerve endings, acting through  $\alpha$ - and  $\beta$ -adrenergic receptors on macrophages, then enhance the release of pro-inflammatory cytokines in plasma; within the brain, the  $\beta$ -adrenergic receptors on microglia fulfill this role<sup>[8]</sup>. Under chronic stress, GC resistance also accounts for T-cell dysfunction, manifested as decreased inhibitory responsiveness on proliferation *in vitro*, redistribution *in vivo*, and a shift in the Th1/Th2 cytokine (pro-/anti-inflammatory) ratio (significantly lower IL-10 levels and a higher IL-6/IL-10 ratio), thereby leading to chronic or non-resolving inflammation<sup>[35,41,42]</sup>. Recent developments in immunology concerning the role of special T-cell subsets in the regulation of inflammation, and the relative expression and function of T<sub>reg</sub> and Th17 cells are of special relevance to Th1 and Th2 cell function<sup>[35]</sup>. The overall effects of T-cell dysfunction may be a potential source of chronic inflammation<sup>[35]</sup>. Unrestrained pro-inflammatory

cytokines, once gaining access to the CNS and interacting with the cytokine network through GC resistance, influence virtually every aspect of brain function, including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, and neuronal circuits with cytokine receptor expression-rich regions that regulate mood, memory, and decision-making, including the limbic and reward circuits (striatum), hypothalamus, and PFC<sup>[34,39]</sup>. The whole profile of the inflammatory processes relevant to stress adaptation (involving behavioral, cardiovascular, metabolic and immunological responses) may be a common mechanism underlying psychiatric disorders such as depression, metabolic disease and CVD.

Optogenetics is a novel method that has advantages including millisecond-scale optical control of defined small-scale events occurring in specified cellular populations. Therefore, it is considered a breakthrough in neuroscience and has already been applied in various studies to modulate synaptic plasticity and control neuronal activity that releases various neurotransmitters and modulators. For instance, optogenetic tools have been used to induce long-term potentiation and long-term depression in research on the synaptic plasticity involved in addiction<sup>[49]</sup>, to selectively stimulate action potentials in ventral tegmental area dopaminergic neurons in freely behaving mammals<sup>[50]</sup>, to detect the co-release of glutamate and acetylcholine from the medial habenula to the interpeduncular nucleus by selectively activating the cholinergic neurons in the former<sup>[51]</sup>, and to test the function of raphe obscurus serotonergic neurons as central respiratory chemoreceptors<sup>[52]</sup>. With new tools allowing control over diverse cellular events, optogenetics has shown great potential in revealing the bi-directional communication between inflammation and stress-related diseases.

#### 4 The “inflammatory dialogue” between heart and brain in the context of stress

It is a long-held belief that there is a bidirectional association of some types of psychiatric disorder and heart diseases with stress<sup>[53-55]</sup>. For example, the prevalence of co-morbid depression in patients with coronary heart dis-

ease (resulting from chronic inflammation in the vascular wall) is three times higher than that in the general population<sup>[56]</sup>. In patients with chronic heart failure, this prevalence might be even higher<sup>[57]</sup>. Meanwhile, depression is also recognized as a major contributor to subsequent cardiac events and even death<sup>[58]</sup>. Converging evidence from both experimental and epidemiological studies shows that increased concentrations of circulating cytokines, such as IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , can be detected not only in patients with depression but also in patients with CVDs such as ischemic heart disease, heart failure, arteriosclerosis, and hypertension<sup>[59-61]</sup>. Understanding the mechanisms underlying the link between the co-morbidity of depression and CVD is of urgent concern to improve public health, despite their complexity and heterogeneity<sup>[53]</sup>. Factors that are common to both mood and cardiovascular regulation may help reveal the mechanisms. These include corticotropin-releasing factor, the HPA axis, the renin–angiotensin–aldosterone system, pro-inflammatory cytokines, and the central neurotransmitter systems, as well as their interactions in the context of stress<sup>[54]</sup>. In the CNS, as discussed above, microglia are the main sources of pro-inflammatory cytokines resulting from communication between immune system and brain. Furthermore, the interactions between microglia and neurons have been shown to play a key role in some neuroinflammation-related brain diseases, yet the underlying mechanisms are not fully understood due to the previous lack of cell type-specific approaches<sup>[62,63]</sup>. Fortunately, optogenetics has made it feasible to explore this field due to its advantages of cell-type specificity and high spatial and temporal resolution.

**4.1 Brain cytokines act as executors in the association between CVD and depression** Numerous clinical studies have shown increased cytokine concentrations in the blood of patients with hypertension, arteriosclerosis, heart failure, and ischemic stroke<sup>[59-61,64]</sup>. Earlier studies revealed that central infusion of pro-inflammatory cytokines such as IL-1 $\beta$  and TNF- $\alpha$  leads to significant hemodynamic and neurohormonal responses (such as increased arterial blood pressure) that are typical of CVDs, sympathetic activity, and the synthesis of renin, aldosterone and vasopres-

sin<sup>[65,66]</sup>. Recent studies further showed that myocardial infarction induces the production of cytokines in the hypothalamus, which modulate neurotransmission in the PVN during the subsequent process of heart failure, resulting in elevated sympathoexcitation<sup>[67-69]</sup>. However, chronic central block of TNF- $\alpha$  in a rat model of heart failure returns the concentrations of several neurotransmitters in the PVN to control levels, while retaining the elevation of renal sympathetic nerve activity<sup>[70]</sup>. Moreover, increases in the central concentrations of anti-inflammatory cytokines (such as IL-10) by cerebroventricular gene transfer ameliorates the hemodynamic and humoral indices of heart failure in the infarcted rat<sup>[71]</sup>. In another study, the central infusion of IL-1 receptor antagonist (IL-1ra) reduces the magnitude of the pressor response to acute stress in healthy rats<sup>[72]</sup>. More recently, experiments suggested that cytokines as neuromodulators exert their action on cardiovascular control through interaction with the brain angiotensin system: pretreatment with either IL-1 $\beta$  or TNF- $\alpha$  enhances the pressor response to the central infusion of angiotensin II<sup>[73]</sup>; the pressor and dipsogenic effects of angiotensin II in mice require the presence of TNF- $\alpha$ <sup>[74]</sup>; blockade of NF- $\kappa$ B in brain ameliorates the development of AngII-induced hypertension, and reduces the expression of angiotensin II type 1 receptors in the heart and the PVN<sup>[75]</sup>.

Major depression is associated with increased levels of inflammatory cytokines in the blood, cerebrospinal fluid, and various brain regions<sup>[76,77]</sup>. Elevated pro-inflammatory cytokines such as IL-1 $\beta$ , IL-6, and TNF- $\alpha$  are positively related to individual symptoms of depression, including fatigue, cognitive dysfunction, and impaired sleep, as well as a factor of treatment resistance<sup>[78]</sup>. Among them, IL-1 $\beta$  and TNF- $\alpha$  play important roles in the pathology of depression<sup>[34,39]</sup>. For example, infusions of IL-1 $\beta$  or TNF- $\alpha$  into wild-type mice evokes depressive behavior<sup>[79]</sup>, whereas mice lacking caspase-1 (an enzyme essential for IL-1 synthesis) display reduced “sickness behavior”<sup>[80]</sup>. Furthermore, deletion of genes for TNF- $\alpha$  receptors in mice has anti-depressive effects.

The pathophysiological mechanisms linking depression with inflammation include the modulation of synaptic

plasticity, dysregulation of neuroendocrine function, and abnormal metabolism of neurotransmitters involved in mood regulation, such as serotonin, dopamine, and norepinephrine<sup>[35]</sup>. In a rat model of depression in response to chronic mild stress, the development of anhedonia was reported, accompanied by dysfunction of the HPA axis and increased expression of IL-1 $\beta$  and TNF- $\alpha$  in the hypothalamus, pituitary, and plasma<sup>[81]</sup>. Similar disturbances have also been found in rats with post-infarct heart failure. Furthermore, in infarcted rats, peripheral inhibition of TNF- $\alpha$  attenuates the symptoms of anhedonia<sup>[82]</sup> and decreases the sympathetic drive and angiotensin receptor type 1 expression in the brain<sup>[83]</sup>.

Of note, pro-inflammatory cytokines are also important modulators of the hormonal and behavioral components of the stress response<sup>[7]</sup>. Under stress stimuli, increased IL-1 $\beta$  mRNA and/or protein expression occurs not only in peripheral tissues but also in the brain (e.g., hypothalamus and hippocampus). IL-1 $\beta$  also plays a key role in the activation of the HPA axis, while central infusion of IL-1ra reduces the circulatory response to the stressor<sup>[84]</sup>. Cytokines are likely to act as “executors” in the pathogenesis of some CVDs and depression associated with stress<sup>[85]</sup>.

**4.2 HPA axis dysregulation underlies the association between CVD and depression** The HPA axis promotes survival and adaptation to stress by increasing vascular tone and ensuring energy availability through its end products such as cortisol in humans and corticosterone in rodents; moreover, it plays a pivotal role in the stress response<sup>[86]</sup>. One of the main roles of GCs in the stress response is to prime the metabolic, autonomic, psychological, hemostatic, and cardiovascular components in preparation for environmental stress stimuli<sup>[87]</sup>. The permissive role of GCs enhances the vascular and metabolic effects of other stress hormones, such as catecholamines, glucagon, and angiotensin II, through enhancement of not only the expression of  $\alpha$ 1 and angiotensin II receptors but also the binding capacity of  $\beta$ -adrenergic receptors<sup>[88-90]</sup>. Another role of GCs is performing suppressive-like actions on inflammation, cellular proliferation, and tissue repair to avoid “overshooting” and self-injury or circula-

tory collapse<sup>[87,91]</sup>. The third role of GCs is inducing insulin resistance in muscle by partitioning of body composition. Long-term exposure of tissues to GCs due to chronic activation of the HPA axis may result in specific conditions such as major depression, metabolic syndrome and even CVDs associated with negative GC effects<sup>[86]</sup>.

A variety of related CVD risk factors such as abdominal obesity, hypercholesterolemia, hypertriglyceridemia, hypertension and glucose intolerance, are associated with dysregulation of the HPA axis<sup>[92]</sup>. Excessive GCs affect specific cardiovascular risk factors, including body composition, plasma lipoprotein and carbohydrate metabolism, endothelial function, oxidative stress, vascular tone, inflammation and tissue repair, and emotional dysregulation. Increasing clinical evidence shows the presence of hypercortisolism, flattening of diurnal cortisol slope, and increased evening cortisol concentrations in patients with coronary artery disease (CAD)<sup>[93]</sup>, and HPA axis dysfunction has been implicated in its pathogenesis<sup>[46,86]</sup>.

In major depression, the phenotype of HPA axis dysregulation is similar to that in CAD patients, resulting in either chronically excessive secretion of cortisol or the flattening of diurnal cortisol slope and increased evening cortisol concentrations due to GR resistance<sup>[34,39,43,45,94]</sup>.

Although further investigations are warranted, current research findings suggest a dominant role for the HPA axis in the association between CVDs and depression<sup>[53]</sup>. HPA axis dysregulation not only influences cardiovascular risk factors in depressed patients but is also implicated in the pathogenesis of CAD and thus has been used to predict death in the depressed male CAD patient<sup>[95]</sup>. Moreover, a previous study showed that the severity of depressive symptoms is significantly related to the incidence rate of metabolic syndrome, partially mediated by HPA axis function, as reflected by urinary cortisol levels<sup>[96]</sup>. In addition, cortisol might be another risk factor for depression and CVD, and common polymorphisms related to altered HPA axis function might increase the risk of both depression and CVD<sup>[97,98]</sup>.

Taken together, when psychological stress-related information is conveyed to the brain, the limbic regions that

subserve higher brain functions related to cognition process it and determine the phenotype of the stress response, by regulating the activity of the HPA axis and the ANS in a top-down manner, on the basis of genetically predisposed early-life experiences. In the context of chronic stress, the elevation of CRH levels resulting from impaired negative feedback regulation of HPA function (caused by the effect of pro-inflammatory cytokines on GC receptors) elevates the outflow of the SNS (through CRH-expressing neurons projecting from the PVN to the locus coeruleus) and thus produces more pro-inflammatory cytokines, intensifying the stress-response system both peripherally and within the brain<sup>[11]</sup>. Moreover, vagal withdrawal in response to stress might also intensify the inflammatory processes. The chronic inflammatory processes under conditions of stress, characterized by a hyperactive HPA axis and increasing production of pro-inflammatory cytokines dominated by GC resistance, can induce the development of stress-related diseases such depression and CVD. Optogenetics may be a potent tool for future research focusing on the neuronal circuits involved in the inflammatory mechanism of interaction between heart and brain (Fig. 1).

## 5 Optogenetics: a potent tool in neuroscience to explore higher-order brain functions

In neuroscience, understanding the system-level pro-

cesses governing higher-order brain functions, such as emotion, perception, and cognition, is a long-term pursuit. Yet, neither current pharmacological (limited by temporal resolution) nor electrophysiological (lack of cell type-specific targets) techniques fully match the speed and heterogeneity of the neuronal system. By combining the use of light and genetically encoded light-sensitive proteins, optogenetics allows cell type-specific targeted, fast (millisecond-scale) control of precisely defined events such as gain or loss of function in biological systems, even in freely-moving animals. It is also a suitable tool for the analysis of the global phenotype of dysfunctional circuits<sup>[99,100]</sup>. Thus, optogenetics offers a potent perturbational tool for understanding the causal link between neural activity patterns and behavior underlying psychiatric disorders such as depression, anxiety, autism and schizophrenia<sup>[101-103]</sup>.

Optogenetics involves two main classes of single-component microbial opsins that are widely used in neuroscience. The first class consists of gain-of-function opsins such as channelrhodopsin (ChR). A recently developed variant is ChR2, which is a cation channel activated by blue light, resulting in depolarization and even action potentials at the cellular level with or without ensuing synaptic currents<sup>[104,105]</sup>. The second class comprises the loss-of-function halorhodopsin (HR), a fully-developed variant of which is *Natronomonas pharaonis* HR, a chloride pump




Fig. 1. Schematic of inflammatory responses to chronic stress. See text for details. ANS, autonomic nervous system; CRH, corticotropin-releasing hormone; CVD, cardiovascular disease; GCs, glucocorticoids; HPA axis, hypothalamic–pituitary–adrenocortical axis; PNS, parasympathetic nervous system; SNS, sympathetic nervous system.



activated by yellow light, resulting in hyperpolarization at the cellular level<sup>[106]</sup>.

Genetic-based strategies that use optogenetics to deliver opsins to distinct neuronal populations can be classified into two types<sup>[99,100]</sup>: one uses cell type-specific promoters to drive transgene expression, and the other is through a recombinase-dependent system if the promoters are too large for the viral vector or if optimal opsin expression is unattainable; in the latter case, opsin expression is restricted to cells carrying Cre recombinase when delivered to transgenic rodents expressing Cre. By stereotaxic injection, the viral vector carrying the opsin gene under the control of cell-specific promoters can be delivered to target regions. Then, through an optical-neuronal interface composed of permanent optical fiber implants that deliver light from a laser or from a light-emitting diode directly targeting the opsin-expressing region, gain- or loss-of-function can be evoked in awake, freely moving rodents by means of a light pulse<sup>[107]</sup>.

Limbic regions that are responsible for regulating HPA axis and ANS stress responses, including the amygdala, hippocampus, and medial PFC (mPFC), interact with circuits responsible for memory, emotion, and reward systems and are also relevant to the development of psychiatric illnesses, as revealed by the use of optogenetics in animal models of such diseases<sup>[108]</sup>. For example, the amygdala has been implicated in the neuronal circuitry of anxiety disorders; yet, it is challenging to fully elucidate the highly heterogeneous population of functionally distinct subnuclei within the amygdala and their complex interconnectivity. By targeting basolateral amygdala (BLA) neurons, optical stimulation of BLA terminals projecting to the central nucleus of the amygdala have anti-anxiety effects in mice, and these effects are reversible during optical inhibition of the same pathway<sup>[102]</sup>. This study highlights the excellent precision of optogenetics in studying highly complex microcircuits, and may help identify key target regions for future treatments. Optogenetics has also shown potentials in studies of depressive behaviors in mice susceptible to chronic social defeat stress: optogenetic stimulation of the mPFC resulting in antidepressant effects suggests that

lower PFC activity mediates depressive-like behaviors<sup>[101]</sup>. Using the reversible loss-of-function of optogenetics based on cell type-specific targeting of CA1 excitatory neurons and temporal precision in a mouse model of contextual fear conditioning, one study on remote memories showed that the hippocampus not only encodes and temporarily stores memories (held by current theory) but is also persistently involved in real-time remote memory recall through the dynamics of retrieval strategies that involve both the anterior cingulate cortex and CA1<sup>[109]</sup>.

In summary, these findings and the ground-breaking progress in optogenetics presented here can serve as a basis for future studies exploring the role of specific neuronal populations in cognitive and neuropsychiatric processes, and enable temporally, genetically, and spatially resolved dissection of the underlying neuronal circuits<sup>[100,109]</sup>.


## 6 Translational implications of the “inflammatory dialogue” between heart and brain in the context of stress

The neural control of stress is a complex process involving the integration of actual and potential outcome information. Circuits in the limbic forebrain process psychological stressor-related information and determine the response in a top-down manner, in anticipation of or in reaction to stressful events on the basis of prior experiences or innate programs<sup>[2,110]</sup>. The top-down strategy may likely depend on higher cognitive brain areas and their downstream effects on many processes<sup>[31]</sup>. Therefore, borrowing concepts and tools from emotion and cognitive neuroscience is necessary for understanding the interaction of the neuroendocrine and immune systems underlying the inflammatory responses to psychological stressors<sup>[1]</sup>. This will help to elucidate the hierarchical, temporal, and spatial communication patterns linking the brain, the stress-perceiving system, and the neuroendocrine and peripheral immune responses to acute and chronic psychological stress in different diseases<sup>[111]</sup>. It is important to identify the basic psychological mechanisms associated with the relevant brain regions and signaling, which are subsequently processed through neuroendocrine efferent pathways

to immunocompetent cells in the peripheral system<sup>[112]</sup>. Dysregulation of the HPA axis is known to be involved in inflammatory response-related diseases under stress, such as metabolic disease, CVD and depression. Moreover, HPA axis pathology is closely associated with altered activation or volumes of the hippocampus, amygdala, and PFC<sup>[32]</sup>. Thus, appropriate initiation and cessation of HPA axis stress responses are vital for both homeostasis and adaptation to adverse events. Strategies to control the HPA axis stress response in a top-down manner through limbic circuits are important for both basic research and clinical practice<sup>[19]</sup>. Fortunately, with the emergence of optogenetics, these are no longer impossible tasks in the study of the nervous system.

As shown above, the use of optogenetics to identify novel mechanistic-based therapeutic targets in limbic regions has yielded promising findings. Chronic inflammatory processes under conditions of stress, which are characterized by hyperactivity of the HPA axis and increasing production of pro-inflammatory cytokines dominated by

GC resistance<sup>[18]</sup>, is another field that awaits extensive investigation using optogenetics. Limbic brain structures modulate anticipatory HPA responses to stress and are logical candidates for the neural and feedback regulation of the HPA axis with respect to prior experiences based on learning, emotion, and memory<sup>[2]</sup>. Moreover, GRs in the hippocampus and cortical output circuits play an important role in inhibition of anticipatory HPA axis stress responses through GC effects<sup>[2]</sup>. Since GCs have cell type-specific effects and different cell types express variable amounts of mineralocorticoid receptors and GR when exposed to variable hormone levels due to regulation<sup>[26]</sup>, traditional endocrinological and pharmacological approaches are limited. Therefore, genetic approaches using cell-specific manipulation of regulatory proteins should be considered. In this respect, optogenetics may provide a necessary and sufficient method for future research directed at determining how GCs act on different cell types and in brain regions (including limbic structures) that produce such profoundly different immunomodulatory outcomes at the system,



**Fig. 2.** The medial prefrontal cortex (mPFC) is a potential target for optogenetic perturbation in the context of stress. The mPFC functions as a principal limbic structure in initiating and coordinating the psychogenic stress response. In humans, mPFC dysfunction is linked to stress-related disease such as depression. The prelimbic cortex (PL), one of the most important subregions of the mPFC in response to psychogenic stress, preferentially inhibits the autonomic nervous system (ANS) and hypothalamic–pituitary–adrenocortical (HPA) axis via its glutamatergic projection to inhibitory paraventricular nucleus relays. With the optogenetic perturbational system, opsin genes can be delivered to glutamatergic neurons in the PL by stereotaxic virus injection under the control of calcium/calmodulin-dependent protein kinase II $\alpha$  (CaMKII $\alpha$ ) promoter. The optical fiber is then implanted through a guide cannula above the PL to set up an optical-neural interface. After expression of the opsin proteins, photostimulation is available to fulfill the role of gain- or loss-of-function in freely moving rodents. The readout systems, including behavior tests, cardiovascular parameters and biochemical indexes in plasma such as cytokines, GCs and catecholamines, help to reveal the causal links between neuronal activity and stress responses.

cellular, and molecular levels. The use of optogenetics involves modulating the HPA axis in response to stress in a top-down manner through limbic regions involved in cytokine effects on behavior (Fig. 1). The strategy is based on concepts borrowed from emotion and cognitive neuroscience<sup>[19]</sup> and might further identify targets for therapeutic intervention in the future (Fig. 2). All these efforts will help to fully elucidate the common background of depression and CVD.

## 7 Conclusion

In chronic inflammatory responses to psychological stress, the interaction between cytokines and the HPA axis results in GC resistance, which leads not only to hyperactivation of the HPA axis (characterized by elevation of GCs and CRH), but also to a self-amplifying vicious cycle of inflammatory responses. Moreover, GC resistance further intensifies the stress-response system both peripherally and centrally, involving behavioral, cardiovascular, metabolic, and immunological responses that consist in the common background of depression and CVD. This inflammatory process also represents a potential “dialogue” between heart and brain. Optogenetics, with advances of cell-type specificity and high spatial and temporal resolution, aims to translate this elusive dialogue to identify novel therapeutic targets within the limbic regions in a top-down manner. Optogenetics will be essential for both basic and clinical research that explores the common mechanisms in stress-related diseases, for the benefit of public health.

**Acknowledgments:** We thank Dr. Jie Tu, Dr. Fan Yang, Dr. Jianqing Pan and Dr. Yi Lu for their valuable comments on this manuscript. This review was supported by the National Natural Science Foundation of China (30970942, 91132306), the National Basic Research Development Program (973 program) of China (2010CB529605, 2011CB504405), the “Hundred Talents Program” of the Chinese Academy of Sciences, the Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies, and a Shenzhen Governmental Basic Research Grant.

## References:

- [1] Kemeny ME, Schedlowski M. Understanding the interaction between psychosocial stress and immune-related diseases: A stepwise progression. *Brain Behav Immun* 2007, 21: 1009–1018.
- [2] Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. *Nat Rev Neurosci* 2009, 10: 397–409.
- [3] Joels M, Baram TZ. The neuro-symphony of stress. *Nat Rev Neurosci* 2009, 10: 459–466.
- [4] Paul H B. Stress and the inflammatory response: A review of neurogenic inflammation. *Brain Behav Immun* 2002, 16: 622–653.
- [5] Khansari DN, Murgu AJ, Faith RE. Effects of stress on the immune system. *Immunol Today* 1990, 11: 170–175.
- [6] Steinman L. Elaborate interactions between the immune and nervous systems. *Nat Immunol* 2004, 5: 575–581.
- [7] Garcia-Bueno B, Caso JR, Leza JC. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. *Neurosci Biobehav Rev* 2008, 32: 1136–1151.
- [8] Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, *et al.* Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. *Neuroscience* 2005, 135: 1295–1307.
- [9] Lucas S-M, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. *Br J Pharmacol* 2006, 147: S232–S240.
- [10] Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. *Ann N Y Acad Sci* 2009, 1179: 1–18.
- [11] Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 2003, 160: 1554–1565.
- [12] Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. *Front Behav Neurosci* 2009, 3.
- [13] Miller GE, Chen E, Fok AK, Walker H, Lim A, Nicholls EF, *et al.* Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling. *Proc Natl Acad Sci U S A* 2009, 106: 14716–14721.
- [14] Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. *JAMA* 2007, 298: 1685–1687.
- [15] de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci* 2005, 6: 463–475.
- [16] Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, *et al.* Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. *Am J Psychiatry* 2006, 163: 1630–1633.
- [17] Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. *Brain Behav Immun* 2007, 21: 374–383.
- [18] Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid

- receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. *Brain Behav Immun* 2007, 21: 9–19.
- [19] Rohleder N, Wolf JM, Wolf OT. Glucocorticoid sensitivity of cognitive and inflammatory processes in depression and posttraumatic stress disorder. *Neurosci Biobehav Rev* 2010, 35: 104–114.
- [20] Herman JP, Figueiredo H, Mueller NK, Ulrich-Lai Y, Ostrander MM, Choi DC, *et al.* Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness. *Front Neuroendocrinol* 2003, 24: 151–180.
- [21] Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. *Psychol Bull* 2004, 130: 601–630.
- [22] Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, *et al.* A mechanism converting psychosocial stress into mononuclear cell activation. *Proc Natl Acad Sci U S A* 2003, 100: 1920–1925.
- [23] Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. *Brain Behav Immun* 2005, 19: 493–499.
- [24] Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. *Nat Rev Immunol* 2005, 5: 243–251.
- [25] Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. *Circulation* 2000, 101: 2338–2341.
- [26] Sorrells SF, Caso JR, Munhoz CD, Sapolsky RM. The stressed CNS: When glucocorticoids aggravate inflammation. *Neuron* 2009, 64: 33–39.
- [27] Lehnert H, Schulz C, Dieterich K. Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus. *Neurochem Res* 1998, 23: 1039–1052.
- [28] Reul JM, Labeur MS, Wieggers GJ, Linthorst AC. Altered neuroimmunoenocrine communication during a condition of chronically increased brain corticotropin-releasing hormone drive. *Ann N Y Acad Sci* 1998, 840: 444–455.
- [29] Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. *Ann N Y Acad Sci* 1993, 697: 173–188.
- [30] Tafet GE, Bernardini R. Psychoneuroendocrinological links between chronic stress and depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2003, 27: 893–903.
- [31] McEwen BS. Physiology and neurobiology of stress and adaptation: Central role of the brain. *Physiol Rev* 2007, 87: 873–904.
- [32] McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease. *Ann N Y Acad Sci* 2010, 1186: 190–222.
- [33] Galea I, Bechmann I, Perry VH. What is immune privilege (not)? *Trends Immunol* 2007, 28: 12–18.
- [34] Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008, 9: 46–56.
- [35] Capuron L, Miller AH. Immune system to brain signaling: Neuropsychopharmacological implications. *Pharmacol Ther* 2011, 130: 226–238.
- [36] McEwen BS. Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. *Eur J Pharmacol* 2008, 583: 174–185.
- [37] Quan N, Whiteside M, Herkenham M. Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. *Neuroscience* 1998, 83: 281–293.
- [38] Banks WA. The blood-brain barrier in psychoneuroimmunology. *Immunol Allergy Clin North Am* 2009, 29: 223–228.
- [39] Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. *Biol Psychiatry* 2009, 65: 732–741.
- [40] Dunn AJ. Cytokine activation of the HPA axis. *Ann N Y Acad Sci* 2000, 917: 608–617.
- [41] Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. *Ann N Y Acad Sci* 2006, 1069: 62–76.
- [42] Adrian J D. The HPA axis and the immune system: A perspective. *NeuroImmune Biol* 2007, 7: 3–15.
- [43] Pariante CM. Depression, stress and the adrenal axis. *J Neuroendocrinol* 2003, 15: 811–812.
- [44] Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. *Biol Psychiatry* 2001, 49: 391–404.
- [45] Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, *et al.* Cortisol circadian rhythm alterations in psychotic major depression. *Biol Psychiatry* 2006, 60: 275–281.
- [46] Nijm J, Jonasson L. Inflammation and cortisol response in coronary artery disease. *Ann Med* 2009, 41: 224–233.
- [47] Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. *Ann N Y Acad Sci* 2009, 1179: 86–105.
- [48] Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages *in vitro* and in lipopolysaccharide-induced endotoxin shock in mice. *Infect Immun* 2002, 70: 6068–6074.
- [49] Pascoli V, Turiault M, Luscher C. Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour. *Nature* 2012, 481: 71–75.
- [50] Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecea L, *et al.* Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. *Science* 2009, 324: 1080–1084.
- [51] Ren J, Qin C, Hu F, Tan J, Qiu L, Zhao S, *et al.* Habenula cholinergic neurons corelease glutamate and acetylcholine and activate postsynaptic neurons via distinct transmission modes. *Neuron* 2011,

- 69: 445–452.
- [52] DePuy SD, Kanbar R, Coates MB, Stornetta RL, Guyenet PG. Control of breathing by raphe obscurus serotonergic neurons in mice. *J Neurosci* 2011, 31: 1981–1990.
- [53] de Jonge P, Rosmalen JGM, Kema IP, Doornbos B, van Melle JP, Pouwer F, *et al.* Psychophysiological biomarkers explaining the association between depression and prognosis in coronary artery patients: A critical review of the literature. *Neurosci Biobehav Rev* 2010, 35: 84–90.
- [54] Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. *Stress* 2009, 12: 1–21.
- [55] Poole L, Dickens C, Steptoe A. The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation. *J Psychosom Res* 2011, 71: 61–68.
- [56] Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, *et al.* Depression and coronary heart disease. *Circulation* 2008, 118: 1768–1775.
- [57] Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, Johnson AK. Heart failure and the brain: new perspectives. *Am J Physiol Regul Integr Comp Physiol* 2003, 284: R259–276.
- [58] Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, *et al.* Depression and cardiac mortality: results from a community-based longitudinal study. *Arch Gen Psychiatry* 2001, 58: 221–227.
- [59] Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. *J Psychosom Res* 2002, 52: 1–23.
- [60] Mann DL. Inflammatory mediators and the failing heart. *Circ Res* 2002, 91: 988–998.
- [61] Savoia C, Schiffrin EL. Inflammation in hypertension. *Curr Opin Nephrol Hypertens* 2006, 15: 152–158.
- [62] Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms Underlying Inflammation in Neurodegeneration. *Cell* 2010, 140: 918–934.
- [63] Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. *Physiol Rev* 2011, 91: 461–553.
- [64] Welsh P, Lowe GD, Chalmers J, Campbell DJ, Rumley A, Neal BC, *et al.* Associations of proinflammatory cytokines with the risk of recurrent stroke. *Stroke* 2008, 39: 2226–2230.
- [65] Kannan H, Tanaka Y, Kunitake T, Ueta Y, Hayashida Y, Yamashita H. Activation of sympathetic outflow by recombinant human interleukin-1 beta in conscious rats. *Am J Physiol* 1996, 270: R479–R485.
- [66] Kimura T, Yamamoto T, Ota K, Shoji M, Inoue M, Sato K, *et al.* Central effects of interleukin-1 on blood pressure, thermogenesis, and the release of vasopressin, ACTH, and atrial natriuretic peptide. *Ann N Y Acad Sci* 1993, 689: 330–345.
- [67] Francis J, Zhang ZH, Weiss RM, Felder RB. Neural regulation of the proinflammatory cytokine response to acute myocardial infarction. *Am J Physiol Heart Circ Physiol* 2004, 287: H791–H797.
- [68] Kang YM, Ma Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin–angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor- $\kappa$ B. *Cardiovasc Res* 2008, 79: 671–678.
- [69] Kang YM, Zhang ZH, Xue B, Weiss RM, Felder RB. Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. *Am J Physiol Heart Circ Physiol* 2008, 295: H227–H236.
- [70] Kang YM, He RL, Yang LM, Qin DN, Guggilam A, Elks C, *et al.* Brain tumour necrosis factor- $\alpha$  modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure. *Cardiovasc Res* 2009, 83: 737–746.
- [71] Yu Y, Zhang ZH, Wei SG, Chu Y, Weiss RM, Heistad DD, *et al.* Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. *Circ Res* 2007, 101: 304–312.
- [72] Ufnal M, Sikora M, Szczepanska-Sadowska E. Interleukin-1 receptor antagonist reduces the magnitude of the pressor response to acute stress. *Neurosci Lett* 2008, 448: 47–51.
- [73] Ufnal M, Dudek M, Żera T, Szczepańska-Sadowska E. Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II. *Brain Res* 2006, 1100: 64–72.
- [74] Sriramula S, Haque M, Majid DSA, Francis J. Involvement of tumour necrosis factor- $\alpha$  in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. *Hypertension* 2008, 51: 1345–1351.
- [75] Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J. Angiotensin II-induced hypertension is modulated by nuclear factor- $\kappa$ B in the paraventricular nucleus. *Hypertension* 2012, 59: 113–121.
- [76] Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. *J Affect Disord* 2010, 120: 245–248.
- [77] Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, *et al.* Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. *Mol Psychiatry* 2007, 13: 717–728.
- [78] Robert D. Cytokine, sickness behavior, and depression. *Immunol Allergy Clin North Am* 2009, 29: 247–264.
- [79] Bluthé RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, *et al.* Synergy between tumor necrosis factor  $\alpha$  and interleukin-1 in the induction of sickness behavior in mice. *Psychoneuroendocrinology* 1994, 19: 197–207.
- [80] Mastrorandi C, Whelan F, Yildiz OA, Hannestad J, Elashoff D, McCann SM, *et al.* Caspase 1 deficiency reduces inflammation-induced brain transcription. *Proc Natl Acad Sci U S A* 2007, 104: 7205–7210.

- [81] Grippo AJ, Francis J, Beltz TG, Felder RB, Johnson AK. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. *Physiol Behav* 2005, 84: 697–706.
- [82] Grippo AJ, Francis J, Weiss RM, Felder RB, Johnson AK. Cytokine mediation of experimental heart failure-induced anhedonia. *Am J Physiol Regul Integr Comp Physiol* 2003, 284: R666–R673.
- [83] Guggilam A, Patel KP, Haque M, Ebenezer PJ, Kapusta DR, Francis J. Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. *Eur J Heart Fail* 2008, 10: 625–634.
- [84] O'Connor KA, Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, *et al.* Peripheral and central proinflammatory cytokine response to a severe acute stressor. *Brain Res* 2003, 991: 123–132.
- [85] Shi P, Raizada MK, Sumners C. Brain cytokines as neuromodulators in cardiovascular control. *Clin Exp Pharmacol Physiol* 2010, 37: e52–e57.
- [86] Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? *Cardiovasc Res* 2004, 64: 217–226.
- [87] Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. *Endocr Rev* 2000, 21: 55–89.
- [88] Fujiwara T, Cherrington AD, Neal DN, McGuinness OP. Role of cortisol in the metabolic response to stress hormone infusion in the conscious dog. *Metabolism* 1996, 45: 571–578.
- [89] Goldstein RE, Cherrington AD, Reed GW, Lacy DB, Wasserman DH, Abumrad NN. Effects of chronic hypercortisolemia on carbohydrate metabolism during insulin deficiency. *Am J Physiol* 1994, 266: E618–E627.
- [90] Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. *J Hypertens* 2002, 20: 965–973.
- [91] Munck A, Náray-Fejes-Tóth A. Glucocorticoids and stress: permissive and suppressive actions. *Ann N Y Acad Sci* 1994, 746: 115–130.
- [92] Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? *Biol Psychiatry* 2004, 55: 1–9.
- [93] Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Björntorp P. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. *J Intern Med* 2003, 254: 386–390.
- [94] Leonard BE. The concept of depression as a dysfunction of the immune system. *Curr Immunol Rev* 2010, 6: 205–212.
- [95] Jokinen J, Nordström P. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients. *J Affect Disord* 2009, 116: 88–92.
- [96] Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schragger M, *et al.* Hypercortisolemic depression is associated with the metabolic syndrome in late-life. *Psychoneuroendocrinology* 2007, 32: 151–159.
- [97] Koeijvoets KCMC, van der Net JB, van Rossum EFC, Steyerberg EW, Defesche JC, Kastelein JJP, *et al.* Two Common haplotypes of the glucocorticoid receptor gene are associated with increased susceptibility to cardiovascular disease in men with familial hypercholesterolemia. *J Clin Endocrinol Metab* 2008, 93: 4902–4908.
- [98] Vedder H, Schreiber W, Schuld A, Kainz M, Lauer CJ, Krieg JC, *et al.* Immune-endocrine host response to endotoxin in major depression. *J Psychiatr Res* 2007, 41: 280–289.
- [99] Deisseroth K. Optogenetics. *Nat Methods* 2011, 8: 26–29.
- [100] Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. *Neuron* 2011, 71: 9–34.
- [101] Covington HE, Lobo MK, Maze I, Vialou V, Hyman JM, Zaman S, *et al.* Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. *J Neurosci* 2010, 30: 16082–16090.
- [102] Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, *et al.* Amygdala circuitry mediating reversible and bidirectional control of anxiety. *Nature* 2011, 471: 358–362.
- [103] Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. *Nat Rev Neurosci* 2012, 13: 251–266.
- [104] Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. *Nat Neurosci* 2005, 8: 1263–1268.
- [105] Zhang F, Wang LP, Boyden ES, Deisseroth K. Channelrhodopsin-2 and optical control of excitable cells. *Nat Methods* 2006, 3: 785–792.
- [106] Zhang F, Wang LP, Brauner M, Liewald JF, Kay K, Watzke N, *et al.* Multimodal fast optical interrogation of neural circuitry. *Nature* 2007, 446: 633–639.
- [107] Aravanis AM, Wang LP, Zhang F, Meltzer LA, Mogri MZ, Schneider MB, *et al.* An optical neural interface: in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology. *J Neural Eng* 2007, 4: S143–156.
- [108] Sidor MM. Psychiatry's age of enlightenment: optogenetics and the discovery of novel targets for the treatment of psychiatric disorders. *J Psychiatry Neurosci* 2012, 37: 4–6.
- [109] Goshen I, Brodsky M, Prakash R, Wallace J, Gradinaru V, Ramakrishnan C, *et al.* Dynamics of retrieval strategies for remote memories. *Cell* 2011, 147: 678–689.
- [110] Jankord R, Herman JP. Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. *Ann N Y Acad Sci* 2008, 1148: 64–73.
- [111] Wilbrecht L, Shohamy D. Neural circuits can bridge systems and cognitive neuroscience. *Front Hum Neurosci* 2010, 3: 81.
- [112] Gadek-Michalska A, Bugajski J. Interleukin-1 (IL-1) in stress-induced activation of limbic-hypothalamic-pituitary adrenal axis. *Pharmacol Rep* 2010, 62: 969–982.